User:Mr. Ibrahem/Oxford–AstraZeneca COVID-19 vaccine
Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca / From Wikipedia, the free encyclopedia
Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Covishield and Vaxzevria, is a COVID-19 vaccine.[1][22] It is used in people over the age of 17 to prevent COVID-19.[1] The initial trials found that it decreases the risk of symptomatic COVID-19 by 60 to 74%.[1] Some countries have limited its use to older people due to concerns of side effects in younger people.[23] The vaccine is given as two doses 4 to 12 weeks apart by injection into a muscle.[1]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Vaxzevria,[1] Covishield[2][3] |
Other names | Verity, AZD1222,[4][5] ChAdOx1 nCoV-19,[6] ChAdOx1-S,[7] COVID-19 Vaccine AstraZeneca,[8][9] AZD2816[10] |
License data | |
Pregnancy category | |
Routes of administration | Intramuscular |
Drug class | COVID-19 vaccine[1] |
Legal status | |
Legal status |
Most side effects are mild to moderate and resolve within a few days.[1] These may include injection site pain, headache, tiredness, muscle pain, and nausea.[1] Rare side effects may include low platelets, facial palsy, blood clots, Guillain-Barré syndrome, anaphylaxis, and capillary leak syndrome.[1] There is no evidence of specific harms with use in pregnancy, though such use has not been well studied.[24] It is a viral vector vaccine, meaning that it is made up of another virus (adenovirus) that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus.[1]
On 30 December 2020, the vaccine was approved for use in the United Kingdom.[25] It has subsequently been authorized for use at some level in at least 182 countries as of 2022.[26] It has been approved for an Emergency Use Listing by the World Health Organization (WHO).[27] It was developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca.[28][29] As of January 2022 more than 2.5 billion doses of the vaccine have been given worldwide.[28] It costs about 2 to 5 USD per dose.[30] The vaccine is stable at refrigerator temperatures for 6 months.[31]